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Objective. Limited information is available on the incidence of rare thyroid cancer (TC) subtypes: anaplastic 33 
(ATC) and medullary (MTC). The aim of this study was to describe incidence variations and trends across 34 
European countries of all TC subtypes.  35 
Materials and Methods. We used the RARECAREnet database including 80,721 TC incident cases in the 36 
period 2000-2007 from 77 population-based cancer registries (CRs) in Europe. In the trend analyses, we 37 
included 68,890 TC cases from 53 CRs with at least 6 years of incidence data in the years 2000-2007.  38 
Results. In Europe age-standardised incidence rates (ASR) in women were <0.3/100,000 for MTC and ATC 39 
whereas ASR were 5.3/100,000 for papillary thyroid cancer (PTC) and 1.1/100,000 for follicular TC (FTC). 40 
Corresponding ASRs in men were <0.2/100,000 for MTC and ATC, 1.5 for PTC and 0.4 for FTC. Across 41 
countries and in both sexes the incidence of FTC and MTC was moderately correlated (r~0.5) with that of 42 
PTC, while a less marked correlation (r<0.4) emerged for ATC ASRs. The changes of the PTC ASRs across 43 
countries and time were weakly (r<0.3) or moderately (r~0.5) correlated to the changes of the other subtypes 44 
for both sexes.  45 
Conclusion. The huge increase and heterogeneity between countries of PTC incidence has a small influence 46 
on the trends and variations of MTC and ATC in Europe. Large-scale epidemiological and clinical registry-47 
based studies are warranted to increase knowledge about the rarest TC subtypes. This information would be 48 








Thyroid cancers (TCs) include follicular cell-derived carcinomas, classically defined as differentiated thyroid 55 
cancer (DTC) (i.e. papillary thyroid cancer (PTC); follicular thyroid cancer (FTC); Hürtle cell carcinomas and 56 
poorly differentiated thyroid cancer (PDTC)) and medullary thyroid cancer (MTC) which arises from the 57 
neuroendocrine parafollicular C cells. Anaplastic thyroid cancer (ATC) is a very rare entity supposed to derive 58 
from undifferentiated epithelial cells 1.  59 
 60 
Worldwide trends in TC incidence have been largely driven by an increase in PTC as opposed to other 61 
histological types 2 3 4 5. Thus, much attention has been given to PTC with controversy surrounding the likely 62 
reasons for the observed epidemic 6. Increased medical surveillance and widespread use of ultrasound 7 5 are 63 
likely explanations 8. 64 
 65 
Ionising radiation exposure, mainly in childhood and adolescence 5, represents the most accepted risk factor 66 
associated with DTC, especially PTC 9 10. Among eating habits, iodine intake represents one of the most 67 
discussed elements, because its deficiency is associated with FTCs, while there is some weak evidence that 68 
observed increases in dietary iodine intake may be responsible for the increasing incidence of PTC11. 69 
Evidence for other risk factors such as low intake of fruits and vegetables; cruciferous vegetables intake; 70 
alcohol consumption, sex hormones 12 and obesity 13 14 remains controversial 5 15 16.  71 
 72 
In contrast, limited information is available on the incidence, trends and risk factors of the rarest TC subtypes: 73 
anaplastic thyroid cancer (ATC) and medullary thyroid cancer (MTC) 17 18 19. It is not clear whether the 74 
widespread use of ultrasound and fine needle biopsies on thyroid nodules is affecting the incidence of FTC, 75 
MTC 20 and ATC. Against this background, our aim was to describe the overall incidence and changes in 76 




Material and methods 79 
 80 
We used the database of the RARECAREnet (www.rarecarenet.eu) project, which includes incidence and 81 
follow-up data provided by 94 European population-based cancer registries (CRs) for patients with cancer 82 
diagnosed between Jan 1, 1978, and Dec 31, 2007. Our analyses refer to the period 2000-2007. To analyse 83 
incidence, we used 77 CRs with data for at least 3 years of incidence between 2000 and 2007, including all 84 
the 24 countries contributing to RARECAREnet (Austria, Belgium, Bulgaria, Croatia, Czech Republic, Estonia, 85 
Finland, France, Germany, Iceland, Ireland, Italy, Latvia, Lithuania, Malta, Norway, Poland, Portugal, Slovakia, 86 
Slovenia, Spain, Switzerland, The Netherlands and United Kingdom) and 45% of EU28 population (excluding 87 
Norway, Switzerland, and Iceland, which are not EU members) (Supplementary Table 1). We excluded 11 88 
anatomical-site-specific CRs to avoid any incomplete coverage of some cancers affecting multiple sites and 89 
six CRs because the percentage of unspecified morphologies (ICD-O3 codes: 8000-8010) was >15%. To 90 
analyse incidence trends over time, we used 53 CRs, with data available for at least 6 years of incidence in the 91 
study period (2000-2007) (Supplementary Table 1). 92 
 93 
Incident TC cases were defined according to ICD-O-3 topography code C73. Morphologies were grouped into 94 
major similar histological types 21 including papillary (8050,8052,8260,8263,8340-8344,8350,8450), follicular 95 
(8290,8330-8335), medullary (8246,8345-8347,8510) anaplastic including poorly differentiated (8012,8020-96 
8035,8190,8337) and unspecified (8000-8010). All the remaining morphologies were combined into the group 97 
“all other morphologies”. Cases first discovered at autopsy or by death certificate only were excluded (n=1,235 98 
from the incidence analyses and n=1,134 from the incidence trends analyses), leaving 80,721 TC cases in the 99 
incidence analyses and 68,890 in the incidence trend analyses. 100 
 101 
Age-standardised incidence rates (ASR) per 100,000 person-years were standardised to the European 102 
population (1960). Analysis of incidence trends was performed for Europe as a whole and by country, 103 
according to three time intervals (2000-2002; 2003-2004; 2005-2007). The statistical significance of incidence 104 
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differences (ASR variation % in 2005-2007 versus 2000-2002) was tested with the Z-test 22. Pearson 105 
correlation coefficients (r) of PTC versus each of the other subtypes were estimated across countries, in the 106 
overall period of the study (years 2000-2007) and per each time interval included in the trend analysis (2000-107 





TC incidence 113 
In Europe, in 2000-2007, the TC incidence rate was 7.1/100,000 in females and 2.4/100,000 in males with a 114 
female to male ratio of 2.97 (Table 1). PTC was the most common subtype constituting 73% and 63% of all 115 
TCs in females and males, respectively. FTC was the second most common subtype; however, its incidence 116 
rate was 5 times lower than that of PTC in females (1/100,000) and about 4 times lower in males 117 
(0.4/100,000). ASRs ≤0.3/100,000 in both females and males emerged for MTC (0.3 and 0.2/100,000, 118 
respectively) and ATC (0.1 and 0.1/100,000, respectively) (Table 1). The female to male ratio differed for MTC 119 
and ATC with female incidence rates 1.4 times that of males. 120 
 121 
Figure 1 reports TC incidence rates by age group and subtype in both females and males. The incidence peak 122 
differed across subtypes and by sex; PTC was most common in females aged 50-54 years and males aged 123 
55-59 years, FTC in females aged 70-74 years and males aged 75-79 years, MTC in females aged 65-69 124 
years and males aged 70-74 years and ATC in both females and males aged 80-84 years.  125 
 126 
 PTC demonstrated the widest variability across Europe with an approximately 8-fold difference in ASRs 127 
across countries (Figure 2). In females, PTC ASRs ranged from 2/100,000 in the UK, Ireland and The 128 
Netherlands to >10/100,000 in Italy, Iceland, Portugal and France. In males, PTC ASRs ranged from 0.7 in 129 
Bulgaria, Northern Ireland and Wales to 4 in Italy and Iceland (7-fold higher).  130 
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FTC ASRs across countries varied by 3 times in females; ranging from <0.6/100,000 in The Netherlands, 131 
Bulgaria and Malta to >1.5/100,000 in Austria, Latvia and, Lithuania (Figure 2). In males, FTC ASRs ranged 132 
from 0.2/100,000 in Norway, Poland and Bulgaria to 0.7 and 0.8/100,000 in Switzerland and Austria, 133 
respectively (an almost  5-fold difference).  134 
MTC and ATC ASRs were low (≤0.5/100.000) with limited differences across countries in both sexes. In 135 
females, MTC ASRs ranged from 0.1/100,000 in Bulgaria and Malta to 0.5/100,000 in Croatia and Austria 136 
(Figure 2). In males, MTC ASRs were 0.3-0.4/100,000 in Austria, Italy and France. ATC ASRs were 137 
<0.3/100,000 in women and <0.2/100,000 in men in all countries and <0.1/100,000 in both sexes in Croatia, 138 
Scotland, England, Latvia, and Bulgaria and Finland (Figure 2). Note: In Finland coding problems could not be 139 
ruled out completely.  140 
 141 
Across countries and in both sexes the incidence of FTC and MTC was moderately correlated (r~0.5) with that 142 
of PTC, while a less marked correlation (r<0.4) emerged for ATC ASRs (Figure 2).  143 
 144 
TC incidence trends 145 
In Europe, TC ASRs increased in the years 2000-2007 in both females and males (variations +25% and 146 
+26%, respectively; p<0.01 for both) (Table 1). PTC was the subtype with the highest and most significant 147 
ASR increase (+33% and +39% in females and males, respectively). Significant but smaller increases were 148 
observed for FTC in females (ASR from 0.9/100,000 to 1/100,000) and for MTC in males (ASR from 149 
0.17/100,000 to 0.19/100,000). No significant changes over time in ASRs were observed for the other 150 
subtypes in females or males. 151 
 152 
In females (Figure 3), the PTC ASR significantly increased in most countries but with different magnitudes. 153 
The variation of ASRs between 2000-2002 and 2005-2007 was >50% in Portugal, Lithuania, Slovenia, Czech 154 
Republic, Latvia, Belgium and Ireland and, about 40% in Italy, Croatia, Austria, Switzerland, Bulgaria, England 155 
and Netherlands, and <30% in Slovakia, Germany, Scotland and Poland (Supplementary Table 2). In some 156 
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other countries (e.g. France, Spain), the PTC ASR did not significantly increase over the study period. The 157 
FTC ASRs increased in Ireland, England and Austria (77%, 32% and 25%, respectively), while they decreased 158 
in Latvia (-45%), Germany, Slovakia and Poland (-30%) (Supplementary Table 2). The ASRs of the MTC and 159 
ATC did not significantly change over time across countries. Moreover, the changes of the PTC ASRs across 160 
countries and time were weakly (r<0.3) or moderately (r~0.5) correlated to the changes of other TC subtypes 161 
(Figure 3).  162 
 163 
In males (Figure 4), the PTC ASR significantly increased in most countries with variations >100% in Latvia, 164 
Portugal, Switzerland, and Malta, and about 40-50% in most of the other countries investigated 165 
(Supplementary Table 2). Variations <25% were observed in Netherlands, Germany and Finland, while a 166 
significant decrease was observed only in Spain (ASR from 2.3 to 1.3; -45%). FTC ASRs significantly 167 
increased only in Ireland (147%), Wales (107%), Portugal (92%) and Austria (28%), while they decreased in 168 
Slovenia (-63%) and Germany (-28%). MTC ASRs increased in Croatia and Belgium (213% and 70%, 169 
respectively) and decreased in Norway and Austria (-49% and -31%, respectively) (Supplementary Table 2). 170 
ATC ASRs increased only in England (97%) and decreased in Scotland and Germany (-68% and -49%, 171 
respectively) (Supplementary Table 2). The changes of the PTC ASRs across countries and time were weakly 172 
(r<0.3) or moderately (r~0.5) correlated to the changes of the other subtypes (Figure 4). 173 
 174 
 175 
Discussion  176 
 177 
This is the first study, to our knowledge, to report incidence and incidence trends of rare thyroid histotypes in 178 
Europe and in each EU country. ATC and MTC ASRs have limited geographical variations across European 179 
countries in both sexes and incidence trends are stable. ATC trends in Europe are coherent with those 180 
observed in the USA 23, 24 and in the Republic of Korea 25. Regarding MTC, in the USA an increase of MTC 181 
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was observed  26 whereas in Europe, we observed a significant increase of MTC only in males in Belgium and 182 
Croatia. The present study confirms a large variation of PTC and FTC incidence across European countries 183 
and in both sexes. Finally, the moderate correlation (r<0.5) of PTC ASRs with the ASRs for other TC subtypes 184 
across countries, supports the hypothesis that recent PTC epidemic is not affecting the incidence of rarest TC 185 
subtypes.  186 
 187 
The study confirms that in Europe PTC and FTC were much more frequent compared to MTC and ATC, were 188 
diagnosed at younger ages, and were more common in females than in males. These differences have been 189 
largely attributed to the age related differences in the use of health services 27. Intense surveillance of thyroid 190 
nodules and thyroid function tend to occur in young and middle-age women due to events related to 191 
reproduction and perimenopausal and postmenopausal symptoms. The role of female hormones has also 192 
been suggested in the aetiology of DTC, however, conclusive studies are still lacking 28. Conversely, men 193 
make frequent medical visits after middle age because of various chronic conditions 29.   194 
 195 
Differences across countries in incidence and trends were almost exclusively limited to PTC. Substantial 196 
evidence  suggests that overdiagnosis is a likely culprit for the different TC incidence across countries, almost 197 
exclusively limited to PTC 8. Diagnostic changes accounted for 60% of TC cases diagnosed in 2003–2007 in 198 
women aged under 80 years in France, Italy, the United States, Australia, and the Republic of Korea, and 199 
approximately 50% in other countries, except Japan (30%) 30 8. Overdiagnosis has led to an increase of 200 
treatment procedures such as surgery and radioactive iodine treatment during the recent years 5 31, leading 201 
scientific societies to update guidelines in order to avoid any unnecessary diagnostic procedures on incidental 202 
thyroid nodules 32 33 24. The American Thyroid Association (ATA) guidelines 34 and the American College of 203 
Radiology 35 have recently stressed the importance of the sonographic pattern of the thyroid nodules for 204 




While the epidemiological studies on DTC are numerous 5, limited information are available on risk factors for 207 
the rarest TC subtypes, as MTC and ATC. MTC may exist as a hereditary tumour (about 25% of cases) within 208 
the complex of multiple endocrine neoplasia type 2A (MEN 2A) and type 2B (MEN 2B) and, more commonly, 209 
as a sporadic form (70% of cases). For this latter type, aetiological factors are not fully known except for 210 
somatic RET or RAS mutations 36. An association between sporadic MTC (sMTC) and history of thyroid 211 
nodules or adenomas (12-fold risk) was reported in the past 17. More recently, Kalezic et al. 18 confirmed that 212 
history of goitre and thyroid nodules (OR 11.29, 95% CI 1.16 - 73.45, p<0.001) were independent  risk factors 213 
for sMTC. Smoking history was associated with a reduced risk for sMTC in both papers 17 18. Authors 214 
postulated an ability to decrease thyroid-stimulating hormone secretion and an innate anti estrogenic effect of 215 
smoking 18. Additionally, other risk factors such as menarche after 14 years 18, height (higher risk in taller 216 
subjects), hypertension, gallbladder disease and allergies have been reported 17.  Interestingly, an average 217 
prevalence of 0.14% of occult MTC has been reported in a series 7897 autopsies in patients without known 218 
thyroid disease and authors demonstrated that routine calcitonin screening applied to general population with 219 
nodular thyroid disease would be not cost effective 20. 220 
 221 
 222 
ATC is one of the most aggressive malignant tumours in humans, with a median overall survival of no more 223 
than 6 months 21. A next generation sequencing (NGS) analysis on a large series of ATC recently 224 
demonstrated that ATC can be divided into 3 clusters according to the genetic features from which ATC 225 
derives 37 supporting the hypothesis of ATC as the final event of a pre-existing PTC or FTC rather than a de 226 
novo tumour. Not surprisingly, ATC is typically diagnosed in elderly patients with 67% of ATC patients 227 
diagnosed at age >70 years. A history of goitre, low educational level and type B blood group have been 228 
recognized as independent prognostic factors in a large case-control study 19.  229 
 230 
The major strengths of this study are the population based design and the availability of the largest well 231 
documented TC series (70,000 cases in 8 years) in Europe. The main limitation is the period analysed. 232 
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Indeed, we report on patients diagnosed from 2000 to 2007. However, these are the only and most recent 233 
available data that allow studying TC incidence by subtype across Europe.  234 
 235 
 236 
In conclusion, MTC and ATC incidence trends in Europe are stable and not correlated to the incidence 237 
increase of PTC. Epidemiological data on MTC and ATC are currently still scant. Thus, collaboration with 238 
clinical registries will be essential to enrich population-based data with information on risk factors, tumour 239 
dimension, stage, pathological and molecular features and treatment especially for MTC and ATC for which 240 
knowledge is still limited. To this end we call the European Reference Network (ERN) on rare cancers 241 
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Tables and Figures legends 374 
 375 
Table 1. Number of incident cases and age-standardised incidence rates (ASR)* together with incidence 376 
trends in Europe by thyroid cancer histological type in females and males. Europe, 2000-2007 377 
* Per 100,000, age-standardised to the European population (1960) 378 
** ASR in 2005-2007 versus 2000-2002 379 
*** including poorly 380 
 381 
Figure 1. Incidence rate by age group by thyroid cancer histologycal type in females (A) and males (B) 382 
 383 
Figure 2.  Age-standardised incidence rates (ASR)* by country and thyroid cancers histological type§ in 384 
females and males with correlation coefficients with PTC ASR 385 
* Per 100,000, age-standardised to the European 386 
§ Note: a different scale has been used for ASR in TC subtypes 387 
 388 
Figure 3. Thyroid cancers age-standardised incidence rates (x 100,000) in females, by subtype, country*, 389 
period of diagnosis of PTC versus each of the other subtype 390 
* Countries are ranked by incidence rate in 2005-2007. Arrow pointing upwards identify significant increase; 391 




Figure 4. Thyroid cancers age-standardised incidence rates (x 100,000) in males, by subtype, country*, period 394 
of diagnosis of PTC versus each of the other subtype 395 
* Countries are ranked by incidence rate in 2005-2007. Arrow pointing upwards identify significant increase; 396 
arrow pointing downwards identify significant decrease 397 
 398 
Supplementary Table 1. Cancer registry (CR) included in the incidence and trends analysis together with the 399 
mean population and the proportion (%) of national population covered abd the years included in the analyses 400 
Supplementary Table 2. Age-standardised incidence rates (ASR)* and number of incident cases for thyroid 401 
cancer by histoligical type, country and period in females and males with Pearson correlation coefficients (r) 402 
between papillary with the other histological type per each time period (2000-2002; 2003-2004; 2005-2007). 403 
Countries are ranked by incidence rate in the last period in decreasing order 404 
 405 
 406 
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